Mesena 80 render (Madrid)

Results 302022

MATINI

WILL CH

October 27th, 2022


Disclaimer

This Presentation neither constitutes nor forms part of any offer for sale or invitation to purchase or subscribe for, or request for an offer of purchase or subscription, of the shares belonging to Metrovacesa, SA ("Metrovacesa"). This Presentation, as well as the information included therein, neither constitutes nor forms part of (i) any contract or commitment of purchase or subscription of shares in accordance with the Securities Market Law, or (ii) an offer of purchase, sale or exchange of shares, or a solicitation of any type of voting rights in the jurisdiction of Spain, UK, USA or any other. "Presentation" refers to this document and any part or content of this document; any oral presentation, brainstorming session and written or audio material processed or distributed during the meeting related to the Presentation or in any way associated with the Presentation, The Presentation and the information contained in the Presentation may not be reproduced, used, distributed or published, in whole or in part, in any case, except with regard to the information extracted from the Presentation and used for the preparation of analysts' reports in accordance with the applicable regulations. The breach of this obligation may result in a violation of the legislation applying to the securities market and this may lead to civil, administrative or criminal liability. In addition to information related to historical facts, this Presentation may contain forward-looking statements relative to Metrovacesa's sales and results and to other issues such as industry, business strategy, goals and expectations concerning its market position, future operations, margins, profitability, capital investment, own resources and other operational and financial information. Forwardlooking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are not about historical facts. The terms "foresee", "expect", "anticipate", "estimate", "consider", "may" and other similar expressions may identify forward-looking statements. Other forward-looking statements can be identified based on their context. Forward-looking statements are based on numerous hypotheses and assumptions relating to Metrovacesa's present and future business strategy, as well as the environment in which Metrovacesa expects to operate in the future. Forward-looking statements include and involve known and unknown risks, uncertainties and other material factors that may affect the actual results and performance of Metrovacesa or the industry. Therefore, the result and the actual performance may differ materially from those expressed or implied in these statements. None of the forward-looking statements, expectations, or perspectives included in this Presentation should be construed as a prediction or a promise. Neither should it be understood that the forward-looking statements involve any demonstration, promise or warranty whatsoever of the accuracy or completeness of the assumptions or hypotheses which such forward-looking statements, expectations, estimates or forecasts are based on, or, in the case of the assumptions, their full inclusion in the Presentation. Numerous factors may cause Metrovacesa's results or actual performance to be materially different from any future results or performance expressly or implicitly included in any of the aforementioned forward-looking statements. In the event that one or several of the aforementioned risks or uncertainties were to materialise, or in the event that the assumptions prove incorrect, actual results may be materially different from those described, anticipated, expected or projected in the Presentation. Therefore, the recipient of this presentation should not unduly rely on these forward-looking statements and their ability to predict future outcomes. Present and future analysts, securities brokers and investors must operate based on their own judgement as to the suitability and adequacy of the securities in terms of the achievement of their particular goals, having taken into consideration what is specified in this notice and the public information available and having received all the professional advice, or of any other type, deemed necessary or merely convenient in these circumstances, without having relied solely on the information contained in the Presentation. The dissemination of this Presentation does not constitute advice or recommendation by Metrovacesa to buy, sell or trade with Metrovacesa shares, or with any other security. Analysts, securities brokers and investors should take into account that the estimates, projections and forecasts do not guarantee the performance, result, prices, margins, exchange rates and other facts relating to Metrovacesa, which are subject to risks, uncertainties or other variables that are not within Metrovacesa's control, in such a way that the future results and the actual performance could be materially different to that anticipated, projected and estimated. The information contained in this Presentation which is not intended to be all-inclusive, has not been verified by an independent third party and shall not be updated. The information of the Presentation, including the forward-looking statements, refers to the date of this document and does not imply any guarantee for future results. Metrovacesa expressly disclaims any obligation or undertaking to disseminate any updates or revisions of the information, including financial data and forward-looking statements. In this regard, Metrovacesa shall not publicly distribute any revision that may affect the information contained in the Presentation that is derived from changes in expectations, facts, conditions or circumstances on which is based the forward-looking statements, or any other change that occurred on the date of the Presentation or after this date. The data relating to the industry, the market and the competitive position of Metrovacesa contained in this Presentation that are not attributable to a specific source have been extracted from the analyses or estimates made by Metrovacesa and have not been independently verified. In addition, the Presentation may include information related to other companies operating in the same sector and industry. This information comes from public sources and Metrovacesa provides no express or implied representation or warranty, nor assumes any responsibility for the accuracy, completeness or verification of the aforementioned data. Certain statistical and financial information contained in the Presentation are subject to rounding adjustment. Therefore, any discrepancy between the total and the sum of the amounts reflected is due to this rounding off. Some of the indicators of financial and operational management included in this Presentation have not been subjected to a financial audit or verification by an independent third party. In addition, certain figures of the Presentation, which have not been subject to financial audit either, are pro forma figures. Metrovacesa and its employees, executives, directors, advisors, representatives, agents or affiliates assume no liability (for fault or negligence, direct or indirect, tort or contract) for damages that may arise from the use of this Presentation or its content or that, in any case, are related to this Presentation. The information contained in this Presentation does not constitute legal, accounting, regulatory, tax, financial or any other type of advice. The aforementioned information has not been prepared taking into consideration the needs or particular situations nor the investment, legal, accounting, regulatory, tax, or financial goals of the recipients of the information. Solely recipients shall be responsible for forming their own judgment and reaching their own opinions and conclusions with respect to these matters and the market, as well as for making an independent assessment of the information. Solely recipients shall be responsible for seeking independent professional advice in connection with the information contained in the Presentation and any action taken based on such information. No one takes responsibility for the information or for any actions taken by any recipient or any of its directors, executives, employees, agents or associates on the basis of the aforementioned information. Neither this presentation nor any part thereof are contractual in nature, and may not be used to form part of or constitute any kind of agreement. Upon receipt of or attendance to the Presentation, the recipient declares its conformity and, therefore, to be subject to the restrictions specified in the preceding paragraphs.

Agenda

Table of Contents

- **1.** Highlights
- **2.** Business Update
- **3.** Financial Overview
- **4.** Closing remarks
 - Appendices







Jorge Pérez de Leza CEO



Borja Tejada **CFO**

Juan Carlos Calvo Strategy & IR

Mirades (Terrassa, Barcelona)

1. Highlights

Highlights

Good operating performance in 9M

+22% YoY in deliveries / Stable backlog of presales / +64,6% in net profit

Resilient demand for new housing

Despite some slowdown since April 2022 / Limited market supply / Increased market uncertainty

On track to meet key 2022 operational targets

Operational CF ~€150m in FY2022 / Strong coverage ratios for 2023 and 2024

Dividend proposal of \in 1.05 per share ⁽¹⁾

To be paid by year-end / A yield of 17.2% yield ⁽²⁾

Notes: (1) Subject to approval by the General Shareholders' Meeting, called for 29/11/2022 (2) With closing price as of 25/10/2022

Jardines de Tetuán (Madrid

2. Business Update

Key operational data

as of September 30th 2022


(1) Defined as cumulative pre-sales (reservations + contracts) minus deliveries

- (2) ASP = Average Selling Price
- (3) Includes units with construction works completed

(4) Pre-sales in the period, net of cancellations


Sector dynamics

Resilient demand for new housing, although increased uncertainty on the future



Pre-sales Flat pre-sales YoY in BTS

9M22 pre-sales: 1,341 units






Higher unit prices

- +16% YoY in avg. selling price: €323k per unit
 Due to improved product mix as well
- as HPA (avg. +5% in 2022)


Net presales by quarter (# units)



Recent demand trends

- Some slowdown in demand since April, but similar to historical averages (example: number of client visits)
- Longer average selling periods, from a lead to a reservation
- Increased uncertainty for coming quarters due to higher inflation and Euribor rates

Number of client visits: evolution



9

/C.


m

Residential deliveries

On track to meet FY22 targeted 1,600-2,000 units

9M22 deliveries










Operational activity

Providing high visibility for the next few years

Pre-sales backlog

Avg. unit price (ASP): €308k (+10% vs. Dec.21)
71% contracts / 29% reservations
Strong sales coverage for 2023-2024

Backlog evolution in # units:




Units in construction



Units in commercialization





Active units

7,647

active units

New active launches: 1,413 units in 9M22

• 1,873 units in design phase, to initiate commercialisation soon

Pipeline from land under management

Several quality projects in the near term



Growing relevance of land under management in new project launches

- Greater visibility on the transformation of several key land plots from NFP to fully permitted
- To become an important land feeder for new project launches in coming years
- Improving product mix: more presence in the key cities (Madrid, Barcelona, Valencia, etc.)
- **Growing in Madrid**: ~900 units to be launched within 2 years, from land originally under management

In aggregate 2018-2022

- **2.2k units launched** from land originally under management (NFP or pending urbanisation)
- 2.4k units transformed from NFP to fully permitted
- **2.1k units sold** via land sales plus 4.4k units via residential deliveries in the period


Land monetisation

Adapting with flexibility to a more challenging context

Land monetisation in 9M 2022					
Land sales: €30.2m		Others: c.€25m			
P&L €6.0m	book value	se and non-core land. Sale prices in line with weakened on tougher market conditions for rs			
Binding sale contracts	partial cash p	dential and commercial land. Binding contracts impl repayments, and a commitment to formalise at a la f them by the end of 2022			
€24.2m	1	commercial land has also softened on rising financi reased uncertainty			
Others:	• Vita Student	Residence: contract signed in July for the			

Sales of land and commercial assets in 2018-2022, €m

K Total P&L in 2018-2022: €258.7m



Aggregated sales by segment in 2018-2022, €m



mvc.

13

Others: c.€25m **Vita Student Residence**: contract signed in July for the development and sale of a 20,100 sqm building as part of the Oria Complex. Land value: c.€25m



Vita Student Residence

Monteburgos 2 (MB2) office project

Notes:

(1) Includes delivery of Monteburgos 2 office project, the book value of land for the Vita student residence plus two binding contracts for the sale of commercial land plots (Madrid and Palma de Mallorca)



3. Financial Overview

215

Profit & Loss

Summary

ﷺ € m	9M 2021	9M 2022	% Change
Revenues	335.2	351.8	+5.0%
Development	316.0	345.8	
Land sales	19.1	6.0	
Gross Profit	64.7	73.6	13.6%
Development	66.4	73.5	
% gross margin dev`t	21.0%	21.2%	
Land sales	(1.6)	0.1	
Net margin	46.4	54.6	17.5%
EBITDA	29.3	34.1	16.4%
Pretax profit	13.8	23.7	
Net Profit	9.9	16.2	64.6%
Recurring pre-tax profit ⁽¹⁾	19.6	27.8	41.3%

+5% revenues €351.8m

+16.4% EBITDA €34.1m

+64.6% Net Profit €16.2m

Notes: (1) Recurring pre-tax profit: excluding contribution from land sales and variations in the fair value of assets

Net debt Solid financial structure

Net debt details

€ <i>m</i>	Dec. 2021	Sep. 2022
Developer loans	55.9	29.6
Corporate debt	338.6	322.5
Gross Financial Debt	394.5	352.1
Unrestricted cash	231.3	200.1
S/T investment	1.1	0.6
Net Financial Debt	162.1	151.5
Restricted cash ⁽¹⁾	68.3	87.0
% LTV	6.2%	5.9%

>>

A very solid capital structure, but not efficient

- LTV of 5.9% is well below an optimal capital structure and peer group
- Cash balance of €287m is equivalent to 56% of annualised revenues, significantly above normal needs

Evolution of net debt and LTV ratio





Dividend distribution in December is a step towards a more efficient capital structure

4. Closing Remarks

A new dividend announcement

€1.05/share, equivalent to €159m



- Subject to approval on General Meeting, called for 29/11/2022
- Payment expected in December 2022
- The BoD may offer the option to receive payment in cash or in a cash/shares combination, at the discretion of shareholders ⁽¹⁾

A dividend yield of 17.2% ⁽²⁾ and 27.0% yield overall in the year 2022 ⁽³⁾



MVC-

18

Notes:

(1) Limited to a maximum distribution of 3.3 million shares already issued, with pro-rata allocation in case of excess demand. Exchange ratio to be based on market prices, and announced by the BoD after the General Meeting. (2) With closing price as of 25/10/2022. (3) Including €0.60/sh paid in May.

Moving to a more efficient capital structure

 \rightarrow

While keeping prudent debt ratios

Dividend history

€ per share

 $\langle\!\langle$

Total 2019-2022: **€422m** or €2.78 /sh




In excess of ordinary distribution policy


- Distributing current excess cash balance before year-end, as an extraordinary distribution (~€0.55 p.s.)
- On top of the ordinary distribution of cashflow generation (~€0.50 p.s.)
- A move towards a more optimal capital structure

Reflects MVC's strong balance sheet and CF profile

- **12% pro-forma LTV** ratio post dividend, is still prudent: lower than the peers in Spain and Continental Europe
- Future distributions of 80%+ of cashflow generation, subject to a target LTV range of 15%-20%

LTV ratio (%): MVC vs peers average





Notes:

(1) Peers Europe includes Nexity, Kaufman & Broad, Instone and JM. Figures as of latest report date (June or August 2022)

(2) Peers Spain includes Aedas, Neinor and Vía Célere. All figures as per latest report date (June 2022), adjusted for dividends paid in July

(3) Non-restricted cash as of latest report date (June 2022 or later) divided by FY2021 total income



Closing remarks

Good progress on targets and strategy

Market outlook: increased uncertainty

Deteriorating macro context, with unclear impact

MVC is very well positioned to manage the current context

Visibility on future deliveries / Maintaining launches / Flexible to adapt

Delivering on our very attractive dividend profile

Supported by strong CF generation and a solid balance sheet





Profit and Loss

(€m)	9M 2021	9M 2022	YoY
Total Revenues	335.2	351.8	5.0%
Residential Development	316.0	345.8	
Land Sales	19.1	6.0	
Total COGs	(270.4)	(278.3)	
Residential Development	(249.7)	(272.3)	
Land Sales	(20.8)	(5.9)	
Gross Margin	64.7	73.6	13.6%
Gross Margin Development	66.4	73.5	
% Gross margin Development	21.0%	21.2%	2 bp
Gross Margin Land Sales	(1.6)	0.1	
Commercial & other operating costs	(18.3)	(19.0)	
Net Margin	46.4	54.6	17.5%
Wages & Salaries	(11.9)	(14.1)	
Other general expenses	(5.2)	(6.4)	
EBITDA	29.3	34.1	16.4%
Change in fair value of assets	(4.2)	(4.2)	
Net financial results	(11.3)	(6.4)	
Others	(0.0)	0.1	
Pre-tax Profit	13.8	23.7	71.2%
Incomen Tax	(4.0)	(7.5)	
Net Profit	9.9	16.2	64.6%
Recurring pre-tax profit ⁽¹⁾	19.6	27.8	41.3%



A -Total revenues of €351.8m (up 5% YoY)

- Residential revenues of €345.8m (+9% YoY)
- Land sales of €6.0m

B - Gross margin of €73.6m

21.2% margin in residential development

C - Net margin of €54.6m, after direct costs

- D EBITDA of €34.1m (+16.4% YoY)
- E Net profit of €16.2m (+64.6% YoY)

Notes: (1) Recurring pre-tax profit: excluding contribution from land sales and impact from changes in appraisal values

Balance Sheet

(€m)	Dec.21	Sep.22
Investment Property	417.0	298.7
Other non-current assets	159.5	167.5
Total non-current assets	576.5	466.2
Inventory	1,844.0	1,886.4
Land	992.5	970.7
WIP & finished product	851.6	915.7
Cash	299.6	287.1
Other current assets	56.9	60.3
Total current assets	2,200.4	2,233.8
Total assets	2,777.0	2,700.0
Provisions	7.6	8.5
Financial debt	287.4	288.5
Otner non-current liabilities	38.6	39.7
Total non-current liabilities	333.6	336.7
Provisions	28.6	32.4
Financial debt	102.6	59.7
Otner non-current liabilities	232.5	266.1
Total current liabilities	363.7	358.2
Shareholder's funds	2,079.6	2,005.0
Total equity + liabilities	2,777.0	2,700.0



- Healthy balance sheet

- Strong cash position of €287.1m:
 - Unrestricted cash: €200.1m
 - Restricted cash: €87.0m
- Low financial gearing, with an LTV of 5.9%



